Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.
about
Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 DiabetesRegulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding TrialThe Changing Landscape of Alopecia Areata: The Translational Landscape.Emerging treatments in alopecia.Treatments options for alopecia.Mechanisms of human autoimmunity.Treating Alopecia Areata: Current Practices Versus New Directions.Targeting Treg signaling for the treatment of autoimmune diseasesEfficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes.Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies.Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice.The role of lymphocytes in the development and treatment of alopecia areata.Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.A novel therapeutic paradigm for patients with extensive alopecia areata.Restoring regulation - IL-2 therapy in systemic lupus erythematosus.Regulatory T Cells: Central Concepts from Ontogeny to Therapy.Restoring Regulatory T Cells in Type 1 Diabetes.Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.Sequential high- and low-dose systemic corticosteroid therapy for severe childhood alopecia areata.Regulatory T cells in skin.Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine.Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation.Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.Therapeutic potential of low-dose IL-2 in immune thrombocytopenia: An analysis of 3 cases.Treatment strategies for autoimmune encephalitis.Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.Intramuscular triamcinolone acetonide: An undervalued option for refractory alopecia areata.Regulatory T Cells As Supporters of Psychoimmune Resilience: Toward Immunotherapy of Major Depressive Disorder.Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options.Regulatory T-Cells: Potential Regulator of Tissue Repair and Regeneration.Regulatory T Cells in Systemic Sclerosis
P2860
Q26770386-2B1F2273-C483-427A-B6C4-31859A09FCE1Q28554636-A9451774-7023-4223-9F96-789498771715Q33890781-F76D32D4-13CF-4886-AF60-5915E27322D0Q34444226-C1E86AE3-D589-4623-AC02-2DB00C912A7EQ35762063-16CC4C14-3D20-4D05-9128-17D877DE7ECFQ35899439-8D26EEC0-370C-4EDF-AB58-01F222CAC1DCQ36171921-3D70B23D-1342-4E07-8544-DB7751349443Q36372616-7848F273-4800-40A6-B6E9-A17B778D1170Q37076418-F82264AE-7B55-447D-87C8-6DBBBA304BCFQ37155737-9CB10B17-3FE8-4A38-8787-030555CED3D7Q37377103-5979F59B-84CF-44A9-9EBC-DC28C612D0DCQ37720518-F3522FA5-455C-4791-9E3C-6C736E2AC8EEQ38262670-C97D273B-673F-4D03-9CA2-98C286E4489DQ38424758-A52D3894-51C3-495E-81DD-A5B5AF27964EQ38616032-FF694B33-EF03-41AE-89D9-3FD50B3088ADQ38627998-2BABDD42-80BD-43BB-BE9B-380AA286C838Q38807853-85583634-AA79-4049-ADEB-63D1B6C0CA89Q38831003-70BC14BE-8766-41AA-B922-A2540BD0023FQ38860839-7CF92980-A1DA-4F48-B52C-334F1FAE930FQ38927531-5C6BEAC9-AA46-4D43-9FA8-47A601C3B3D5Q38963375-E6CE7643-9068-4096-B1CD-42ADB5FDBD57Q39076924-F3E4B21E-0DD3-4F54-9427-9D530B3502D6Q39099270-F2C682A6-94CA-4132-9A13-1A061F09346FQ39430032-C4CBB5B4-7694-42B1-A69E-171AF4761237Q40108816-C4331BCA-15BB-4BD5-B957-DA84FC0CC791Q40122658-C586ABB6-ADF3-4796-8738-8CA820F7F031Q44479151-C52968FE-695E-4CD9-917C-A5C3F84AA20CQ47578102-E23A14C2-6F1C-420D-A2E8-7B7045C9902DQ48554984-265E49C3-93E9-46E4-8E85-B78508A387F6Q49213573-1D1DB4F8-D819-49B8-90C5-AA366BC3299BQ50030501-6C6EDA78-5E61-4048-8246-84E0AC0603FFQ50115047-BFA90939-E0D1-46DE-A118-E650D0410EDFQ50873069-917DF820-D1A1-4F57-B0CE-9BA116E5E410Q52608611-DC5CC015-A7C6-4C4A-A073-120FA8153B36Q55315323-5C9F1243-7E1B-4104-B944-74A338F2254FQ55399832-EC4AA0FB-2195-40C1-A2B9-C822B7F6A4FAQ58122062-12010F01-8C2A-449E-88C0-8B369F93473F
P2860
Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Effects of low-dose recombinan ...... tory cells in alopecia areata.
@en
type
label
Effects of low-dose recombinan ...... tory cells in alopecia areata.
@en
prefLabel
Effects of low-dose recombinan ...... tory cells in alopecia areata.
@en
P2093
P50
P1433
P1476
Effects of low-dose recombinan ...... tory cells in alopecia areata.
@en
P2093
Catherine Butori
Emeline Castela
Florence Le Duff
Michel Ticchioni
P304
P356
10.1001/JAMADERMATOL.2014.504
P407
P577
2014-07-01T00:00:00Z